Affimer® Drug Conjugates (AffDC) targeting Fibroblast Activation Protein-α deliver highly toxic warheads to the tumor microenvironment by leveraging the pre|CISION® release mechanism

Laura Weatherburn, Scientist II in Bioconjugation at Abzena recently contributed to a scientific poster by Avacta Therapeutics entitled: ‘Affimer® Drug Conjugates (AffDC) targeting Fibroblast Activation Protein-α deliver highly toxic warheads to the tumor microenvironment by leveraging the pre|CISION® release mechanism’.

Antibody-drug conjugates (ADCs) have revolutionized the treatment of multiple diseases in metastatic cancers. Affimer® drug conjugates (AffDC) are a novel class of engineered biotherapeutics designed to deliver highly toxic warheads directly to the tumor microenvironment (TME) by combining two novel delivery systems. The clinically validated pre|CISION® warhead release mechanism which has significant advantages over protease-cleavable linkers in that warhead release is only accomplished with FAP cleavage in the TME (Banerjee et al. 2024, Twelves et al. 2024).

Find out more by downloading the Avacta Therapeutics and Abzena poster today.

Download Poster